Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (349)	1/16/2013 8:54:36 AM
From: PLegee	Read Replies (1) \| Respond to of 368

You have it correct, there is no definitive date and/or conference when the data will be made public. In addition, other than the subjective term "update", there is no set expectation as of what or how much detail will actually be disclosed. SGMO is already on record stating that full results will be posted by YE 2013. Since these trials are `unblinded' and undoubtedly SGMO is already evaluating findings in real time, I am hoping that the interim report at a minimum, improves the current probability of a decisive clinical outcome; a true functional cure. Ongoing patient CD4-T levels and detectable viral loads versus number of treatments at a minimum would be nice; hopefully the data presented will be much more robust than that. I dislike the deliberate strategy of keeping we investors guessing, but after the fiasco three years ago on the DN (SB 509) announcement, Ed has since chosen the low bar tactic on setting expectations. Some are speculating that CROI in March could contain a late entry for an announcement, but others seem to point to conferences in the 2nd quarter as being more likely. The official public company statement form Jan 9th was: "We expect to present preliminary data from these trials in the first half of 2013 and to have the full data set by the end of 2013."